Institut régional du Cancer de Montpellier (ICM)
Hospital
Location:
Montpellier,
France (FR)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer (2020)
Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al.
Journal article
Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3 (2018)
Fasching P, Esteva FJ, Pivot X, Nusch A, Beck JT, Chan A, Pieris-Gunatilaka A, et al.
Conference contribution
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 (2018)
Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al.
Journal article
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project+ (2015)
Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, et al.
Journal article